Search

Reuben Arasaratnam, M.D., M.P.H., Assistant Professor of Internal Medicine at UT Southwestern, has been named one of 11 2022 Scholars in Diagnostic Excellence by the National Academy of Medicine (NAM).

Interstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it particularly difficult to treat. While immunosuppressant drugs are primarily prescribed, they don’t work for all patients.

A healthy diet, regular exercise, and sufficient sleep can help prevent the onset of diabetes, a condition affecting more than 37 million Americans, according to Bethany Agusala, M.D., Assistant Professor of Internal Medicine at UT Southwestern.

Roger H. Unger, M.D., a longtime Professor of Internal Medicine, a preeminent authority on glucagon and the development of diabetes, and the founding Director of the Touchstone Center for Diabetes Research at UT Southwestern Medical Center, died Aug. 22. He was 96.

Two classes of drugs prescribed off-label for some patients with Type 1 diabetes can provide significant benefits but also come with health concerns, according to a study by UT Southwestern Medical Center researchers.

Hip and knee replacements, sports injuries, trauma. That’s typically what comes to mind when one thinks of orthopedic surgery, not diabetes.

Complications after an amputation left Scott Bryson, a 50-year-old father of three, unable to walk. But in June 2023, he took his first steps in nearly a decade after receiving a revolutionary surgical procedure at UT Southwestern Medical Center.

Two genes working in tandem play a critical role in shaping the identity and behavior of prostate cancer cells and their response to treatment, UT Southwestern Medical Center researchers report.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center reported in a retrospective study.